ANDA Sponsors Get Wide-Open Facility Deadline For Priority Review
Executive Summary
User fee legislation says facility information to qualify for priority review must arrive two months in advance of ANDA, conflicting with narrow 'window' in FDA's draft guidance.
You may also be interested in...
CMC Regulatory Updates In Brief: Complete Response Tallies And Guidance On Inhalers, Supplements, Liposomes And H2O2
US FDA attributes 12% of last year's complete responses to manufacturing facility issues. Separately, it proposes a major revision of its 1998 draft guidance on drug quality for metered dose and dry powder inhalers, revises 1999 internal guidance on CMC supplements, and finalizes guidance on CMC considerations for liposomes drafted in 2015, while UK MHRA cautions firms against relying on VHP to sterilize isolator parts.
New ANDA Review Pathways: Should You Be A Priority Or Expedited?
Amid confusion about multiple priority and expedited pathways for US generic drug applications, industry asks which are a true advantage.
New ANDA Review Pathways: Should You Be A Priority Or Expedited?
Amid confusion about multiple priority and expedited pathways for US generic drug applications, industry asks which are a true advantage.